Facebook
X
LinkedIn
Forward
The Latest Breakthroughs in LG-IR-NMIBC (2025)
The American Urological Association is proud to offer The Latest Breakthroughs in LG-IR-NMIBC, a dynamic educational activity designed specifically for the urologic care team. This program addresses key educational gaps and barriers in the management of low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)—as identified in the AUA’s Bladder Cancer Global Needs Assessments.
Stay at the forefront of clinical excellence with the most current insights into LG-IR-NMIBC treatment. Whether you're a urologist, advanced practice provider or part of the urologic care team, this activity will provide timely updates on evolving guidelines, novel therapies and best practices for delivering the highest standard of patient care.
This multi-format learning experience includes:
- A Live Virtual Webinar featuring a multidisciplinary expert panel in a lively, interactive discussion on the latest clinical advances in LG-IR-NMIBC
- An On-Demand Webcast available via AUAUniversity and the AUAUniversity YouTube channel for convenient access anytime, for up to one year
- A Podcast Episode released as part of the highly successful AUAUniversity Podcast series
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- UroGen Pharma, Inc.
Target Audience
- Urologists
- APPs
- Residents/Fellows
Learning Objectives
After participating in this CME activity, participants will be able to:
- Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.
- Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.
- Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.
- Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).
- Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.
- Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.
Welcome and Introductions
Pre-test
Segment 1: Updated clinical evidence and treatment protocols
Segment 2: Clinical decision-making related to risk stratification and surveillance strategies
Segment 3: Evidence-based, patient-centered treatment selection options
Segment 4: Interpret the efficacy and safety profiles of new therapies
Segment 5: New medications in the evolving treatment landscape
Segment 6: Impact of treatment options on patient-reported outcomes
Post-test
Wrap-up
| Name | Company Name | Relationship Type | End Date |
| Donahue, Meredith | No relevant financial relationships to disclose | ||
| Filippou, Pauline | No relevant financial relationships to disclose | ||
| Laviana, Aaron A. | No relevant financial relationships to disclose | ||
| Schmidt, Bogdana | Urogen Pharma | Consultant or Advisor | 12/05/2025 |
EDUCATION COUNCIL DISCLOSURE
Education Council DTL 2025_1.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup DTL 2025_1.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.